Actinium Pharmaceuticals, Inc. has filed an amendment to its previous 8-K report, originally submitted on November 26, 2025. This amendment serves to clarify the company's decision on the frequency of future shareholder advisory votes regarding the compensation of its named executive officers, commonly referred to as 'Say-on-Pay Votes'. The board of directors has determined that these votes will be conducted annually, following a preference expressed by shareholders during the advisory vote held at the Annual General Meeting. The decision will be re-evaluated after the next advisory vote scheduled for the 2031 Annual General Meeting, unless a vote is presented earlier. This amendment does not introduce any new changes to the original report, which primarily focused on the final voting results from the Annual Meeting. The filing is categorized under Item 5.07, which pertains to the submission of matters to a vote of security holders. The company continues to operate under its existing governance framework, with no significant changes to its leadership or operational strategy indicated in this filing.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.